Brutalist Biotech
Max
3
|
5
|
10
|
20
items per feed.
Cutting-edge Biotech news: Presented the old-fashioned way.
Fierce Biotech
Labcorp launches rapid fentanyl test with 48-hour detection window
(1h)
Terremoto takes $108M series C to fuel clinical trials of AKT1 inhibitors
(4h)
FDA official confirms plausible mechanism principles not exclusive to bespoke gene therapies
(10h)
Bain-backed Beeline Medicines buzzes out of stealth with $300M and 5 programs from BMS
(15h)
Cell therapy biotech Obsidian leverages Galera reverse merger to go public
(22h)
BioPharma Dive
Travere wins long-awaited approval for kidney disease drug
(21h)
J&J leans on Tremfya, cancer drugs to overcome Stelara losses
(21h)
Lilly boosts ADC portfolio with CrossBridge Bio deal
(22h)
Novo teams with OpenAI; Ideaya gets muted response to eye drug data
(1d)
Spyre drug for inflammatory bowel disease shows promise in early study
(1d)
Endpoints News
Terremoto raises $108M to make an 'earthquake' in small molecule space
(1h)
Beeline Medicines emerges as Bristol Myers' partner for shelved immunology drugs
(2h)
FDA asks for more data on Lilly’s Foundayo to assess heart, liver risks
(19h)
Replimune looks ahead as repeat CRL speeds the company's decline
(19h)
Revolution Medicines leads latest wave of stock offerings, totaling $1.5B
(22h)
BioSpace
Takeda continues to prune partnerships, cuts ties with mRNA-targeting Veritas In Silico
(1h)
Lilly’s new obesity pill linked to ‘serious’ safety signals, FDA requests more data
(1h)
J&J targets $100B revenue, Replimune rebuffed again and a “Revolution” in pancreatic cancer
(2h)
Could biotech layoffs push life sciences talent to go global?
(6h)
5 biopharma M&A deals where the workforce was the prize
(8h)
STAT News
Trump DOJ report says Biden administration treated anti-abortion protestors unfairly
(1h)
New Bain biotech startup, building on BMS drugs, gets a name and a CEO
(2h)
AI could check millions of CT scans for heart risk. Who will pay for it?
(4h)
Hosting the ‘intellectual wrestling match’ between MAHA, public health
(4h)
Flawed study on the antidepressant Paxil came with a cautionary note — if you knew how to find it
(4h)
BioPharma Trend
Novo Nordisk and OpenAI Team Up to Integrate AI from Discovery to Supply Chain
(21h)
Life Biosciences Gets $80M as Cellular Rejuvenation Enters the Clinic
(5d)
Jeito Closes €1B Fund, Europe's Largest Independent Biopharma Raise
(5d)
Anthropic Pays $400M for an AI Biotech With Fewer Than Ten People
(1w)
Epia Neuro Wants to Decode Brain's Movement Intentions After Stroke
(2w)
Drug Channels
Mapping the Vertical Integration of Insurers, PBMs, GPOs, Specialty Pharmacies, and Healthcare Services: DCI’s 2026 Update
(1d)
Informa Connect’s Life Sciences Pricing & Contracting USA
(2d)
The Net Pricing Revolution in the Drug Channel: What’s Deflating the Gross-to-Net Bubble (rerun)
(5d)
The FTC Blows Up Express Scripts’ PBM Model—and Launches the Net Pricing Drug Channel (rerun)
(6d)
List Price Reductions Will Deflate the Gross-to-Net Bubble–and Threaten Pharmacy and 340B Profits from IRA-Negotiated Drugs (rerun)
(1w)
European Biotechnology Magazine
Novo Nordisk is going all in on AI
(3h)
Can Europe finance and keep its biotech winners?
(4h)
Europe’s distinct biotech venture studio model
(4h)
Adcendo banks US$75m to push ADC pipeline forward
(6h)
Clean Food Group to scale yeast-based oils with £4.5m in the bank
(1d)
Drug Hunter
BHV-2100
(21h)
orforglipron
(2d)
Module 3 Quiz
(2d)
Daraxonrasib (RMC-6236): The 2025 Molecule of the Year
(5d)
relacorilant (CORT125134)
(6d)
Labiotech.EU
Mending university and venture capital relations: is it possible to see eye-to-eye?
(4h)
Can phage therapy answer the booming antibiotic resistance problem?
(1d)
Amgen pipeline’s next growth cycle: replacing its old blockbusters
(2d)
Top biotech deals in March 2026
(5d)
Multi-agent AI delivers reliable and scalable insights for single-cell omics
(5d)
Bio IT World
PARTAGE Method Reveals Genome Regulation in Single Approach
(1d)
CAS Releases Agentic Tool for Literature Discovery
(5d)
'Mini-brain' Model Explores Concussion's Effects at Cellular Level
(6d)
‘Humble’ AI Reveals When It is Uncertain in Diagnoses
(1w)
Inductive Bio on a Winning Streak With ADMET Predictions
(2w)
GEN News
Engineered Miniature CRISPR Boosts Gene‑Editing Efficiency in Human Cells
(13h)
CAR T Cell Therapy Biomanufactured by Cellares Infused Into First Two Patients
(16h)
Regeneron, Telix Launch Up-to-$4.3B Cancer-Focused Radiopharma Drug, Diagnostic Collaboration
(18h)
GLP-1 Drug Improves Liver Health Independent of Weight Loss, Mouse Study Finds
(18h)
AWS Launches Amazon Bio Discovery Agentic AI to Accelerate Drug Development
(22h)
Cure Today
Treating Metastatic TNBC: Dr. Hope Rugo on ADCs and Personalized Therapy
(3w)
Understanding High-Risk Essential Thrombocythemia
(3w)
Son’s Decision to Donate Gave His Father a Second Chance
(4w)
Functional Precision Medicine Advances Brain Tumor Care
(4w)
Home-Based Chemotherapy at Mayo Clinic Shows Safe Option for Patients With Cancer
(4w)
Contract Pharma
Evotec Names Chief Operating Officer
(18m)
FDA Approves Travere’s Filspari for Treatment of Focal Segmental Glomerulosclerosis
(16h)
Labcorp Unites With AWS and Datavant on AI Platform to Accelerate Alzheimer’s Research
(18h)
BostonGene, ImmunoGenesis Partner to Accelerate Development of Immune Checkpoint Inhibitor
(20h)
Parabilis Medicines Updates Executive Leadership Team
(21h)
Pharma Times
Transgene completes randomisation in phase 2 trial of tg4050
(2d)
Bayer wins MHRA approval for Kerendia in heart failure
(2d)
Oxford BioTherapeutics signs collaboration with Bristol Myers Squibb
(6d)
Kainova expands DT 7012 trial into Europe
(6d)
Amgen reports positive phase 3 results for subcutaneous TEPEZZA in thyroid eye disease
(1w)
Medcity News
Heartflow Sues Cardiac AI Rival Cleerly Over Alleged IP Theft
(13h)
Vida Health Teams Up with ŌURA to Provide More Personalized Metabolic Care
(14h)
Bouncing Back From Trial Failure, Travere Wins First FDA Approval in Rare Kidney Disease
(14h)
5 of the Top 10 U.S. Health Systems Are Moving to This New Health IT Category. Here’s Why.
(19h)
Why Synthetic Data is the Antidote to Clinical Trials
(23h)
Chemical & Engineering News
Eric Jacobsen named 2026 F. A. Cotton Medal winner
(1h)
Carter to become next CEO of Dow
(17h)
Business Watch: Borouge International emerges; Regeneron, Telix link for radiopharma
(19h)
Satellite data reveal rising methane levels
(19h)
Academic freedom declines in US and 49 other countries, survey finds
(20h)
The Pharma Letter
FDA demands trial safety data on Foundayo after approval
(1h)
Rubicon enters Indian CNS formulations market with buy of Arinna Lifesciences
(1h)
Obsidian and Galera reveal reverse merger plan
(2h)
OSE Immunotherapeutics evolves leadership team
(3h)
Neomorph secures $100M Series B to scale molecular glue degrader pipeline
(5h)
Targeted Oncology
Ozekibart Plus Chemo Shows Promising Activity in R/R Ewing Sarcoma
(4w)
Reduced CRS Rates Support Wider Adoption of Bispecifics in Myeloma
(4w)
GLSI-100 Vaccine Shows <1% Annual Recurrence Rate in Phase 3 Breast Cancer Trial
(4w)
Treating Triple Negative Breast Cancer in the Frontline Setting
(4w)
Early Phase Evaluation of Intravesical Erdafitinib in NMIBC
(4w)
MedWatch
FDA to review Leo Pharma's hand eczema treatment for youths
(38m)
Industry warns of uncertainty surrounding new EU market protection
(1h)
Long waiting lists and geopolitical headwinds could pose a challenge to Hemab’s IPO plans
(1h)
ALK wins approval for nasal spray in Canada
(2h)
Media: FDA is close to appointing a new head of vaccines and biologics
(2h)
In The Pipeline
Answers and Reasons and Knowing and Thinking
(16h)
Predicting Antibody Binding: No Champagne Just Yet
(1d)
Consider the Selfish Ribosome
(5d)
New Bond Formations Just Keep On Coming
(6d)
Ah, Peptides. Where to Begin?
(1w)
Pharmaphorum
Daiichi exits OTC, with $1.55bn unit sale to Suntory
(23m)
Parkinson's charity partners Biognosys on biomarker project
(1h)
Amazon launches its AI drug discovery platform
(2h)
FDA seeks safety data for Lilly's oral GLP-1 Foundayo
(3h)
FDA renews criticism of trial sponsors over transparency
(1d)
Drug Discovery Weekly
Construction completed on new UK life science facility
(1h)
Access to hyperkalaemia drug expands across England and Wales
(3h)
Immunopeptide could delay inflammatory arthritis, study says
(4h)
Antibody discovery company opens cryo-EM facility in San Diego
(5h)
Laigo Bio announces new CSO as part of board appointments
(20h)
HIT Consultant
The Clinical Resolution Gap: Why AI Can’t Fix Broken MSK Care Platforms
(6h)
Wavelet Medical Secures $7M to Scale AI Fetal Brain Monitoring Globally with Aegis Ventures
(22h)
Finding the Right Five Percent: How Machine Learning Is Reshaping Care Management
(1d)
Ultralight Raises $9.3M to Launch AI-Native Operating System for Healthcare
(1d)
The AI Arms Race: Why PHTI Warns Healthcare ‘Bot Wars’ Are Inflating Medical Costs
(1d)
Insights: Pink Sheet
Prolonged Iran Ports Blockade Risks Drug Shortages, Wider Supply Chain Woes
(8h)
US FDA To Clarify Plausible Mechanism Framework With Genome Editing Guidances, Workshop
(15h)
US FDA’s Literature-Based Leucovorin Approval May Offer A Rare Disease Template
(16h)
Does FDA Untitled Letter For Adcetris Facebook Ads Signal Start Of Social Media Crackdown?
(20h)
US Tariffs To Hit European Pharmaceutical SMEs Disproportionately
(1d)
BioXconomy
Beyond Redaction: Governing Confidential Information in an Era of Expaning Transparency
(1d)
FDA proposes faster Phase I trial approvals to boost US competitiveness
(8h)
Eli Lilly bets $300m on CrossBridge Bio's dual-payload ADC platform
(27m)
FDA stability and gene therapy payment models discussed
(41m)
Biogen’s blueprint for collaboration in China’s thriving pharma landscape
(4h)
BioCentury
Remembering Sofinnova’s Denis Lucquin, father of French biotech
(12h)
Novartis’ Narasimhan joins Anthropic board
(12h)
Zentalis leads movers in trio of ovarian cancer updates
(13h)
Psoriasis paves the way for next-generation TYK2 inhibitors in autoimmunity
(16h)
FDA’s FIH plans. Plus: billion-dollar deals, funds — a BioCentury podcast
(1d)
SCRIP
BMS/Bain $300m Venture Emerges As Beeline With Lead Asset Nearing Pivotal Stage
(2h)
Daiichi Sankyo Tightens Oncology Focus Through OTC Divestment To Suntory
(3h)
Alphamab’s Bispecific Phase III Win In Breast Cancer Lays Runway For Take Off
(4h)
AZ Optimistic On Japan Prospects Despite Pricing, LoE Challenges
(7h)
Great Expectations: Icotyde Could Be J&J’s Biggest Product Ever, Duato Says
(16h)